Figure 6
From: Loss of NR2E3 represses AHR by LSD1 reprogramming, is associated with poor prognosis in liver cancer
Association of AHR and NR2E3 levels with precancerous liver disease and cancer. (a,b) Kaplan-Meier plot survival analysis using two independent liver cancer patient data (GSE10143, N = 162 [left]; GSE10186, N = 89 [right]). Liver cancer patients were dichotomized by relative expression levels of AHR (high vs. low). A significant P value (P < 0.05) was determined by log-rank test. The hazard ratio and 95% confidence interval for each dataset are indicated at the bottom. (c) Quantification of the NR2E3 st aining intensity in normal liver (N = 9), cirrhotic liver (N = 24), and liver tumor (N = 50) tissues. The NR2E3 staining intensity was classified as high (>70%), moderate (between 70 and 30%), low (<30%) and non-detectable. (d) Immunohistochemical staining images of NR2E3 in human cirrhotic and liver tumor tissue using tissue microarray. (e) Overall survival (OS) analysis based on the relative expression levels of NR2E3 mRNAs in liver cancer patients using publically available The Cancer Genome Atlas (TCGA) data (N = 369).
